Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The study included 12 patients who suffer from a subset of Type 1 diabetes known as hypoglycemic unawareness, characterized ...

The stock's fall snapped a three-day winning streak.

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Vertex Pharmaceuticals (VRTX) reached $464.2 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

US biotech major Vertex Pharmaceuticals (Nasdaq: VRTX) has reached a wide-ranging reimbursement deal with NHS England for ...

Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 9% of the investors ...

Investing at least part of the initial $1,000 in an artificial intelligence (AI) stock is a smart move. Despite impressive ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...